RecruitingPhase 3NCT07430306
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
Studying Autosomal systemic lupus erythematosus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AstraZeneca
- Intervention
- Anifrolumab(drug)
- Enrollment
- 245 enrolled
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2026 – 2029
Collaborators
ICON plc
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07430306 on ClinicalTrials.govOther trials for Autosomal systemic lupus erythematosus
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07447986To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus ErythematosusHangzhou Sumgen Biotech Co., Ltd.
- RECRUITINGPHASE1NCT07363590A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)Merck Sharp & Dohme LLC
- RECRUITINGPHASE3NCT07201129A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular TreatmentViatris Innovation GmbH
- RECRUITINGPHASE1NCT07276958A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)Eli Lilly and Company
- RECRUITINGPHASE1, PHASE2NCT07348055A Study of GR1803 in Systemic Lupus ErythematosusGenrix (Shanghai) Biopharmaceutical Co., Ltd.
- RECRUITINGNCT07000110Anifrolumab Malignancy and Serious Infections StudyAstraZeneca
- RECRUITINGPHASE1NCT07318259Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLEChongqing Precision Biotech Co., Ltd
- RECRUITINGPHASE1NCT07331467Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLEChongqing Precision Biotech Co., Ltd